Optimization of Dengue-EDIII – Hepatitis B-VLP Fusion Antigen Protein Expression in Mammalian Cell Systems and Preliminary Immunogenicity Testing in Mice

Ziza Putri Aisyia Fauzi; Eka Nur Fatmawati; Putri Tri Hartini; Yuneka Saristiana; Husnunnisa

Authors

Ziza Putri Aisyia Fauzi Universitas Muslim
Eka Nur Fatmawati Akbid Harapan Mulia Ponorogo Akbid Harapan Mulia Ponorogo
Putri Tri Hartini Universitas Muhammadiyah Riau
Yuneka Saristiana Universitas Kadiri
Husnunnisa Universitas Muhammadiyah Riau

Keywords:

Dengue Virus, Envelope Domain III, Virus-Like Particle, HBcAg, Subunit Vaccin, Mammalian Expression System

Abstract

The development of a safe and effective dengue vaccine remains challenging due to the risk of antibody-dependent enhancement (ADE) associated with imbalanced immune responses. This study aimed to optimize the expression of a dengue virus envelope domain III (EDIII) fusion antigen displayed on Hepatitis B core antigen virus-like particles (VLPs) and to evaluate its preliminary immunogenicity in a murine model. Optimization of antigen design and expression conditions resulted in a substantial increase in VLP production compared with the non-optimized construct. The purified VLPs showed uniform size, proper particle assembly, and preserved antigenic integrity. Immunization of mice induced high titers of EDIII-specific IgG and strong serotype-specific neutralizing antibodies against dengue virus serotype 2, while no antibody-dependent enhancement was detected in vitro. These findings indicate that the optimized EDIII–HBcAg VLP platform is highly immunogenic and demonstrates a favorable safety profile, supporting its potential as a promising subunit vaccine candidate for dengue virus.

References

Crill, W. D., & Roehrig, J. T. (2001). Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. Journal of Virology, 75(16), 7769–7773.

https://doi.org/10.1128/JVI.75.16.7769-7773.2001

Halstead, S. B. (2014). Dengue antibody-dependent enhancement: Knowns and unknowns. Microbiology Spectrum, 2(6), AID-0022-2014.

https://doi.org/10.1128/microbiolspec.AID-0022-2014

Hunsawong, T., Sunintaboon, P., et al. (2019). A single amino acid substitution (F108A) in dengue virus envelope protein improves secretion and antigenicity. Virology, 532, 12–22.

https://doi.org/10.1016/j.virol.2019.03.015

Katzelnick, L. C., Harris, E. (2017). Immune correlates of protection for dengue: State of the art and research agenda. Vaccine, 35(36), 4659–4669.

https://doi.org/10.1016/j.vaccine.2017.07.045

Modis, Y., Ogata, S., Clements, D., & Harrison, S. C. (2004). Structure of the dengue virus envelope protein after membrane fusion. Nature, 427(6972), 313–319.

https://doi.org/10.1038/nature02165

Pitoiset, F., Vazquez, T., Bellier, B. (2015). Enveloped virus-like particle platforms: Vaccines of the future? Expert Review of Vaccines, 14(7), 913–915.

https://doi.org/10.1586/14760584.2015.1047354

Pumpens, P., & Grens, E. (2016). HBV core particles as a carrier for B cell/T cell epitopes. Intervirology, 59(2), 74–80.

https://doi.org/10.1159/000448415

Rey, F. A., Heinz, F. X., Mandl, C., Kunz, C., & Harrison, S. C. (1995). The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. Nature, 375(6529), 291–298.

https://doi.org/10.1038/375291a0

Rothman, A. L. (2011). Immunity to dengue virus: A tale of original antigenic sin and tropical cytokine storms. Nature Reviews Immunology, 11(8), 532–543.

https://doi.org/10.1038/nri3014

Rouvinski, A., Guardado-Calvo, P., Barba-Spaeth, G., et al. (2015). Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature, 520(7545), 109–113.

https://doi.org/10.1038/nature14130

Shukla, R., & Ramasamy, V. (2018). Virus-like particles as vaccine candidates against dengue virus. Journal of Biosciences, 43(1), 1–13.

https://doi.org/10.1007/s12038-017-9728-9

Sukupolvi-Petty, S., Austin, S. K., et al. (2013). Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. Journal of Virology, 87(13), 7429–7440.

https://doi.org/10.1128/JVI.00402-13

Wang, Q., Yang, H., Liu, X., et al. (2013). Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Science Translational Medicine, 8(369), 369ra179.

https://doi.org/10.1126/scitranslmed.aai8336

Whitehead, S. S., Blaney, J. E., Durbin, A. P., & Murphy, B. R. (2007). Prospects for a dengue virus vaccine. Nature Reviews Microbiology, 5(7), 518–528.

https://doi.org/10.1038/nrmicro1690

Zeltins, A. (2013). Construction and characterization of virus-like particles: A review. Molecular Biotechnology, 53(1), 92–107.

https://doi.org/10.1007/s12033-012-9598-4